98%
921
2 minutes
20
Background: Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure activity, speed of brain entry may be an important factor. BRV showed faster entry into the human and non-human primate brain, based on more rapid displacement of SV2A tracer C-UCB-J. To extract additional information from previous human studies, we developed a nonlinear model that accounted for drug entry into the brain and binding to SV2A using brain C-UCB-J positron emission tomography (PET) data and the time-varying plasma drug concentration, to assess the kinetic parameter K (brain entry rate) of the drugs.
Method: Displacement (LEV or BRV p.i. 60 min post-tracer injection) and post-dose scans were conducted in five healthy subjects. Blood samples were collected for measurement of drug concentration and the tracer arterial input function. Fitting of nonlinear differential equations was applied simultaneously to time-activity curves (TACs) from displacement and post-dose scans to estimate 5 parameters: K (drug), K(C-UCB-J, displacement), K(C-UCB-J, post-dose), free fraction of C-UCB-J in brain (f(C-UCB-J)), and distribution volume of C-UCB-J (V(UCB-J)). Other parameters (K(drug), K(C-UCB-J), f(drug), f(C-UCB-J, displacement), f(C-UCB-J, post-dose), f(drug), k(drug), k(C-UCB-J)) were fixed to literature or measured values.
Results: The proposed model described well the TACs in all subjects; however, estimates of drug K were unstable in comparison with C-UCB-J K estimation. To provide a conservative estimate of the relative speed of brain entry for BRV vs. LEV, we determined a lower bound on the ratio BRV K/LEV K, by finding the lowest BRV K or highest LEV K that were statistically consistent with the data. Specifically, we used the F test to compare the residual sum of squares with fixed BRV K to that with floating BRV K to obtain the lowest possible BRV K; the same analysis was performed to find the highest LEV K. The lower bound of the ratio BRV K/LEV K was ~ 7.
Conclusions: Under appropriate conditions, this advanced nonlinear model can directly estimate entry rates of drugs into tissue by analysis of PET TACs. Using a conservative statistical cutoff, BRV enters the brain at least sevenfold faster than LEV.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643320 | PMC |
http://dx.doi.org/10.1186/s13550-022-00944-5 | DOI Listing |
Adv Mater
September 2025
State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China.
Delivering therapeutics across the blood-brain barrier (BBB) remains a major challenge in ischemic stroke therapy. Ischemic stroke induces upregulation of various inflammatory membrane receptors on brain endothelial cells, offering potential entry points for receptor-mediated transcytosis. This study proposes a universal targeting strategy by employing inflammatory pathway antagonists as targeting ligands, which broadens the spectrum of available ligands beyond traditional receptor-binding molecules.
View Article and Find Full Text PDFFront Neurosci
August 2025
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Background: Ischemic stroke (IS), the leading stroke subtype (∼87%), arises from vascular occlusions, triggering brain necrosis through ischemia-reperfusion injury. Ferroptosis, an iron-driven cell death via Fe-mediated lipid peroxidation, is implicated in IS pathology. This study demonstrates that enoyl-coA hydrolase 1 (ECH1) may serve as a peripheral biomarker and therapeutic target for IS based on ferroptosis signaling.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Glioma therapy faces substantial challenges primarily due to the restrictive nature of the blood-brain barrier (BBB), limiting effective drug penetration and reducing therapeutic efficacy. Recent advancements in novel drug delivery systems (DDS), including exosome-mediated carriers, drug conjugates, and ultrasound-assisted delivery, have demonstrated promising results in overcoming these limitations. Exosomes offer superior biocompatibility, efficient BBB crossing, and natural cellular targeting capabilities; drug conjugates enable highly selective drug delivery through tumor-specific ligands; and ultrasound-assisted systems transiently disrupt the BBB to permit greater drug entry.
View Article and Find Full Text PDFBiol Psychiatry Cogn Neurosci Neuroimaging
September 2025
University of Illinois at Chicago, Department of Psychiatry. Electronic address:
Background: Late-life depression (LLD) is associated with negative outcomes including high rates of recurrence and cognitive decline. However, the neurobiological changes influencing such outcomes in LLD are not well understood. Disequilibrium in large-scale brain networks may contribute to LLD-related cognitive decline.
View Article and Find Full Text PDFAustralas Psychiatry
September 2025
Department of Psychological Medicine, School of Medicine, Faculty of Medical and Health Science, The University of Auckland, Auckland, New Zealand.
ObjectivesThere is limited research on entry to aged residential care (ARC) in people living with young-onset dementia (YOD). Most people with YOD eventually require ARC, often in facilities designed for older adults. This study aimed to investigate the time to ARC admission in a previously identified YOD cohort and their health outcomes before and after ARC admission.
View Article and Find Full Text PDF